Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TERT | O14746 | 6/20 | 0.63 |
| ▸ | STAT3 | P40763 | 1/20 | 0.61 |
| ▸ | STAT1 | P42224 | 1/20 | 0.61 |
| ▸ | TOP1 | P11387 | 4/20 | 0.36 |
| ▸ | CYCS | P99999 | 3/20 | 0.35 |
| ▸ | ENPP2 | Q13822 | 1/20 | 0.35 |
| ▸ | ABCG2 | Q9UNQ0 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3465842 | 0.85 | TERT (0.65) | TERTSTAT3STAT1TOP1CYCS | |
| SCHEMBL5319095 | 0.84 | STAT3 (0.64) | TERTSTAT3STAT1TOP1CYCS | |
| SCHEMBL30205816 | 0.84 | STAT3 (0.64) | TERTSTAT3STAT1TOP1CYCS | |
| SCHEMBL473158 | 0.83 | STAT3 (0.86) | TERTSTAT3STAT1TOP1CYCS | |
| SCHEMBL30753635 | 0.83 | STAT3 (0.86) | TERTSTAT3STAT1TOP1CYCS | |
| Iodide SCHEMBL27581324 | 0.83 | STAT3 (0.63) | TERTSTAT3STAT1TOP1CYCS | |
| SCHEMBL1275381 | 0.82 | STAT3 (0.84) | TERTSTAT3STAT1TOP1CYCS | |
| SCHEMBL5470455 | 0.82 | STAT3 (0.66) | TERTSTAT3STAT1TOP1CYCS | |
| SCHEMBL3352961 | 0.81 | STAT3 (0.64) | TERTSTAT3STAT1TOP1CYCS | |
| SCHEMBL7258061 | 0.81 | STAT3 (0.64) | TERTSTAT3STAT1TOP1CYCS |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-115996754-A | Prophylactic and therapeutic immunotherapy of propionibacterium acnes | 免疫之源生物技术有限公司 | 2023-04-21 | — | — | CN | disclosed |
| US-7445641-B1 | Biomaterials modified with superoxide dismutase mimics | PHARMACIA CORPORATION (US) | 2008-11-04 | — | — | US | disclosed |
| US-20070179124-A1 | Substituted Porphyrins | FRIDOVICH IRWIN | 2007-08-02 | — | — | US | disclosed |
| US-20060074062-A1 | Substituted porphyrins | DUKE UNIVERSITY (US) | 2006-04-06 | — | — | US | disclosed |
| US-6916799-B2 | Substituted porphyrins | DUKE UNIVERSITY (US) | 2005-07-12 | — | — | US | disclosed |
| WO-2005044149-A1 | MODIFIED HYALURONIC ACID POLYMERS | PHARMACIA CORPORATION (US) | 2005-05-19 | — | — | WO | disclosed |
| EP-1185312-B1 | BIOMATERIALS MODIFIED WITH SUPEROXIDE DISMUTASE MIMICS | MONSANTO CO (US) | 2005-03-23 | — | — | EP | disclosed |
| EP-1045851-B1 | SUBSTITUTED PORPHYRINS | UNIV DUKE (US) | 2003-04-23 | — | — | EP | disclosed |
| US-20020042407-A1 | Antiinflammatory agents; respiratory system disorders | DUKE UNIVERSITY | 2002-04-11 | — | — | US | disclosed |
| EP-1185312-A2 | BIOMATERIALS MODIFIED WITH SUPEROXIDE DISMUTASE MIMICS | MONSANTO COMPANY (US) | 2002-03-13 | — | — | EP | disclosed |
| EP-1045851-A4 | SUBSTITUTED PORPHYRINS | UNIV DUKE (US) | 2001-05-09 | — | — | EP | disclosed |
| WO-2000072893-A2 | BIOMATERIALS MODIFIED WITH SUPEROXIDE DISMUTASE MIMICS | MONSANTO COMPANY (US) | 2000-12-07 | — | — | WO | disclosed |
| EP-1045851-A1 | SUBSTITUTED PORPHYRINS | DUKE UNIVERSITY (US) | 2000-10-25 | — | — | EP | disclosed |
| US-6087493-A | ENZYME IHIBITORS | REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM (US) | 2000-07-11 | — | — | US | disclosed |
| WO-1999023097-A1 | SUBSTITUTED PORPHYRINS | DUKE UNIVERSITY (US) | 1999-05-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070179124-A1 | Substituted Porphyrins | PPOX, GPX4, PRDX5 | TERT 821/4885STAT3 892/4885STAT1 1589/4885 |
| US-20020042407-A1 | Antiinflammatory agents; respiratory system disorders | LPO, PRDX5, MPO | TERT 3237/4885STAT3 541/4885STAT1 674/4885 |
| US-20060074062-A1 | Substituted porphyrins | PPOX, GPX4, PRDX5 | TERT 821/4885STAT3 892/4885STAT1 1589/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.